Why new cancer treatment discoveries are proliferating

by Karen L. Brooks,University of PennsylvaniaSunil Singhal, MD, examines lung tissue during a surgical procedure using a glowing tumor agent, while a colleague observes. Credit: University of Pe

Updated on: January 08,2024

Why new cancer treatment discoveries are proliferating

by Karen L. Brooks,University of PennsylvaniaSunil Singhal, MD, examines lung tissue during a surgical procedure using a glowing tumor agent, while a colleague observes. Credit: University of Pe

Updated on:January 08,2024

Analysis of radiotherapy and locoregional recurrence in RxPONDER patients

by SWOG Cancer Research NetworkCredit: Unsplash/CC0 Public DomainAn analysis of data on the use of radiation therapy in a large clinical trial of patients with HR+, HER2- breast cancer who had one to

Updated on: December 17,2023

Analysis of radiotherapy and locoregional recurrence in RxPONDER patients

by SWOG Cancer Research NetworkCredit: Unsplash/CC0 Public DomainAn analysis of data on the use of radiation therapy in a large clinical trial of patients with HR+, HER2- breast cancer who had one to

Updated on:December 17,2023

Why millennials should know colon cancer symptoms

by Deb BalzerCredit: Unsplash/CC0 Public DomainMore younger adults are being diagnosed with colon cancer —also known as colorectal cancer—and at more advanced stages of the disease, says the American

Updated on: January 08,2024

Why millennials should know colon cancer symptoms

by Deb BalzerCredit: Unsplash/CC0 Public DomainMore younger adults are being diagnosed with colon cancer —also known as colorectal cancer—and at more advanced stages of the disease, says the American

Updated on:January 08,2024

Racial disparity in pro-metastatic tumor microenvironment among women with residual breast cancer after NAC

byAmerican Association for Cancer ResearchCredit: Unsplash/CC0 Public DomainResidual tumors from Black patients with estrogen receptor (ER)-positive/HER2-negative primary breast cancer treated w

Updated on: December 17,2023

Racial disparity in pro-metastatic tumor microenvironment among women with residual breast cancer after NAC

byAmerican Association for Cancer ResearchCredit: Unsplash/CC0 Public DomainResidual tumors from Black patients with estrogen receptor (ER)-positive/HER2-negative primary breast cancer treated w

Updated on:December 17,2023

Selpercatinib Significantly Improves PFS, Responses in Advanced RET+ Medullary Thyroid Cancer

October 21, 2023Gina MauroSelpercatinib resulted in a statistically significant improvement in progression-free survival and overall response rate compared with cabozantinib or vandetanib in patients

Updated on: October 24,2023

Selpercatinib Significantly Improves PFS, Responses in Advanced RET+ Medullary Thyroid Cancer

October 21, 2023Gina MauroSelpercatinib resulted in a statistically significant improvement in progression-free survival and overall response rate compared with cabozantinib or vandetanib in patients

Updated on:October 24,2023

Nab-paclitaxel does not extend biliary tract cancer survival, but may benefit some

by SWOG Cancer Research NetworkCredit: Pixabay/CC0 Public DomainAdding nab-paclitaxel to a standard treatment of gemcitabine plus cisplatin does not significantly extend median overall survival (OS) t

Updated on: December 17,2023

Nab-paclitaxel does not extend biliary tract cancer survival, but may benefit some

by SWOG Cancer Research NetworkCredit: Pixabay/CC0 Public DomainAdding nab-paclitaxel to a standard treatment of gemcitabine plus cisplatin does not significantly extend median overall survival (OS) t

Updated on:December 17,2023

Pembrolizumab Monotherapy Displays Efficacy in Rare Sarcomas

The PD-1 inhibitor pembrolizumab (Keytruda) displayed activity with a manageable safety profile in patients with certain rare and ultra-raresarcoma histotypes, according to findings from the phase 2 A

Updated on: November 07,2023

Pembrolizumab Monotherapy Displays Efficacy in Rare Sarcomas

The PD-1 inhibitor pembrolizumab (Keytruda) displayed activity with a manageable safety profile in patients with certain rare and ultra-raresarcoma histotypes, according to findings from the phase 2 A

Updated on:November 07,2023

Team learns how to predict triple negative breast cancer recurrence

byIndiana University School of MedicineCredit: Anna CarreraIndiana University School of Medicine researchers have discovered how to predict whether triple negative breast cancer will recur, and

Updated on: December 22,2023

Team learns how to predict triple negative breast cancer recurrence

byIndiana University School of MedicineCredit: Anna CarreraIndiana University School of Medicine researchers have discovered how to predict whether triple negative breast cancer will recur, and

Updated on:December 22,2023

B-Cell Lymphoma Treatment Options

B-Cell Lymphoma Treatment OptionsByJennifer Sabour, MSPublished on March 07, 2022Medically reviewed byDoru Paul, MDWhile B-cell lymphoma always originates in white blood cells

Updated on: January 28,2024

B-Cell Lymphoma Treatment Options

B-Cell Lymphoma Treatment OptionsByJennifer Sabour, MSPublished on March 07, 2022Medically reviewed byDoru Paul, MDWhile B-cell lymphoma always originates in white blood cells

Updated on:January 28,2024

Women with elevated breast cancer risk could see mortality benefit from estrogen-blocking drugs

byGeorgetown University Medical CenterCredit: Unsplash/CC0 Public DomainWhile it has long been recognized that drugs that block the cancer-promoting activity of estrogen reduce risk of developin

Updated on: December 19,2023

Women with elevated breast cancer risk could see mortality benefit from estrogen-blocking drugs

byGeorgetown University Medical CenterCredit: Unsplash/CC0 Public DomainWhile it has long been recognized that drugs that block the cancer-promoting activity of estrogen reduce risk of developin

Updated on:December 19,2023

First test of anti-cancer agent PAC-1 in human clinical trials shows promise

by Diana Yates,University of Illinois at Urbana-ChampaignProcaspase-3 (PC-3) expressions in diverse tumor histologies categorized as moderate-to-strong immunostaining intensities. Credit:B

Updated on: December 27,2023

First test of anti-cancer agent PAC-1 in human clinical trials shows promise

by Diana Yates,University of Illinois at Urbana-ChampaignProcaspase-3 (PC-3) expressions in diverse tumor histologies categorized as moderate-to-strong immunostaining intensities. Credit:B

Updated on:December 27,2023

Mapping oesophageal cancer genes leads to new drug targets

byCancer Research UK| News4 February 2019Mutations that cause oesophageal adenocarcinoma (OAC) have been mapped in unprecedented detail – unveiling that more than half could be targeted by

Updated on: December 19,2023

Mapping oesophageal cancer genes leads to new drug targets

byCancer Research UK| News4 February 2019Mutations that cause oesophageal adenocarcinoma (OAC) have been mapped in unprecedented detail – unveiling that more than half could be targeted by

Updated on:December 19,2023